ERBB2 and breast carcinoma: Indeed, HER2 status was the most powerful over 5 years (p = 0.002, HR = 4.04, CI 1.66–9.8) and with 30 years of breast cancer specific survival (p = 0.0006, HR = 2.88, CI 1.57–5.29).